Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0N9WG
|
|||
Former ID |
DNC007280
|
|||
Drug Name |
N-(4,6-diphenylpyrimidin-2-yl)-3-chlorobenzamide
|
|||
Synonyms |
CHEMBL426390; 820961-63-5; 3-chloro-N-(4,6-diphenylpyrimidin-2-yl)benzamide; N-(4,6-diphenylpyrimidin-2-yl)-3-chlorobenzamide; CTK3E2645; DTXSID50459660; MolPort-007-705-564; BDBM50157667; ZINC13586467; AKOS001552650; MCULE-8841696019; Benzamide, 3-chloro-N-(4,6-diphenyl-2-pyrimidinyl)-
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Structure |
Download2D MOL |
|||
Formula |
C23H16ClN3O
|
|||
Canonical SMILES |
C1=CC=C(C=C1)C2=CC(=NC(=N2)NC(=O)C3=CC(=CC=C3)Cl)C4=CC=CC=C4
|
|||
InChI |
1S/C23H16ClN3O/c24-19-13-7-12-18(14-19)22(28)27-23-25-20(16-8-3-1-4-9-16)15-21(26-23)17-10-5-2-6-11-17/h1-15H,(H,25,26,27,28)
|
|||
InChIKey |
BYALFPUQWRIWML-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 820961-63-5
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Adenosine A1 receptor (ADORA1) | Target Info | Inhibitor | [1] |
KEGG Pathway | cGMP-PKG signaling pathway | |||
cAMP signaling pathway | ||||
Sphingolipid signaling pathway | ||||
Neuroactive ligand-receptor interaction | ||||
Morphine addiction | ||||
NetPath Pathway | TCR Signaling Pathway | |||
RANKL Signaling Pathway | ||||
Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
Reactome | Adenosine P1 receptors | |||
G alpha (i) signalling events | ||||
WikiPathways | Nucleotide GPCRs | |||
GPCRs, Class A Rhodopsin-like | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | 2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.